Table 2.
Comparison of the clinical characteristics and management of NSCLC patients according to the type of ILD
| Characteristic | Total (n = 141) |
IPF-LC (n = 81) |
Non-IPF-LC (n = 60) |
p Value |
|---|---|---|---|---|
| Clinical stage of NSCLC | 0.337 | |||
| I | 46 (32.9) | 31 (38.3) | 15 (25.0) | |
| II | 20 (14.3) | 9 (11.1) | 11 (18.3) | |
| III | 38 (27.1) | 21 (25.9) | 17 (28.3) | |
| IV | 36 (25.7) | 10 (24.7) | 17 (28.3) | |
| KL-6 (U/mL), n = 98 | 983.7 ± 1111.4 | 907.9 ± 900.1 | 1098.4 ± 1376.12 | 0.409 |
| Initial treatment for NSCLC | ||||
| Surgery | 46 (32.6) | 30 (37.0) | 16 (26.7) | 0.194 |
| Lobar resection | 29 (63.0) | 14 (46.7) | 15 (93.8) | |
| Sublobar resection | 17 (37.0) | 16 (53.3) | 1 (6.3) | |
| Chemotherapy | 32 (22.7) | 15 (18.5) | 17 (28.3) | 0.169 |
| Radiotherapy | 31 (22.0) | 19 (23.5) | 12 (20.0) | 0.624 |
| CCRT | 7 (5.0) | 1 (1.2) | 6 (10.0) | 0.042 |
| Best supportive care | 25 (17.7) | 16 (19.8) | 9 (15.0) | 0.465 |
| Treatment of ILD | ||||
| Antifibrotic agent | 70 (49.6) | 65 (80.2) | 5 (8.3) | < 0.001 |
| Corticosteroid ± IS | 54 (38.3) | 29 (35.8)a | 25 (41.7)b | 0.479 |
| Initial treatment | 17 (12.1) | 5 (6.2) | 12 (20.0) | 0.013 |
| Acute exacerbation | 37 (26.2) | 25 (30.9) | 12 (20.0) | 0.147 |
| RT pneumonitis | 5 (3.5) | 2 (2.5) | 3 (5.0) | 0.651 |
| Acute exacerbation | 37 (26.2) | 25 (30.9) | 12 (20.0) | 0.147 |
| Overall mortality | 57 (40.4) | 34 (42.0) | 23 (38.3) | 0.663 |
| AE-related death | 21 (36.8) | 14 (41.2) | 7 (30.4) | 0.409 |
| Infection-related death | 15 (26.3) | 7 (20.6) | 8 (34.8) | 0.232 |
| Unknown | 21 (36.8) | 14 (41.2) | 7 (30.4) | 0.409 |
Data are expressed as mean ± standard deviation for continuous variables and number (percentage) for categorical variables. NSCLC, non-small cell lung cancer; CCRT, concurrent chemoradiation therapy; ILD, interstitial lung disease; IS, immunosuppressants; SCLC, small cell lung cancer; AE, acute exacerbation
a3 patients were treated with steroid as initial treatment and during acute exacerbation
b2 patients were treated with steroid as initial treatment and during acute exacerbation